Determination of MK-287, a new platelet-activating factor antagonist, in plasma and serum by gas chromatography chemical ionization mass spectrometry.
MK-287 is a novel platelet-activating factor antagonist. A sensitive and specific gas chromatographic/mass spectrometric assay has been developed for the determination of the drug in serum and plasma. The assay utilizes an extraction with methyl-t-butyl ether and subsequent trimethylsilylation of the hydroxyl function. The gas chromatographic/mass spectrometric determinations are carried out with temperature-programmed capillary gas chromatography and ammonia negative chemical ionization mass spectrometry. The method has sufficient sensitivity, precision, accuracy and selectivity for the analysis of drug concentrations in clinical samples.
Fisher
A L
AL
Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Morris
M J
MJ
Gilbert
J D
JD
D005663:Furans / Q000097:blood*; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D066298:In Vitro Techniques; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D010975:Platelet Aggregation Inhibitors / Q000097:blood*; D011863:Radioimmunoassay
D005663:Furans; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; C071469:MK 287